How do I get a product approved through ANVISA in Brazil without it taking five years?

Key Takeaways for Investors

• The Clarification Clock Risk: The notorious multi-year delay is rarely due to statutory limitations but is triggered when applicants submit generic global dossiers that fail to address ANVISA’s unique technical parameters, automatically pushing files into lengthy clarification cycles.

• Accelerated Regulatory Pathways: Brazil offers mechanisms designed to potentially expedite market entry, including the Priority Review Pathway (under RDC 204/2017 and RDC 1.001/2025) and the Optimized Pathway, which leverages regulatory reliance on stringent reference authorities such as the FDA and EMA.

• Challenging the Five-Year Narrative: For well-prepared submissions aligned with local requirements from day one, sponsors may expect review timelines broadly aligned with ANVISA's statutory targets of 120 days (priority review) and 365 days (ordinary route). These deadlines may be extended by up to one-third, resulting in maximum review periods of 160 days and 487 days (approximately 16 months), respectively.

• Local Data Priorities: ANVISA maintains an unyielding focus on specific local data variations, particularly regarding pediatrics, Phase I trials, and national supply security, which cannot be bypassed via a simple copy-and-paste of US or European files.

• Transparency as an Asset: The agency has significantly modernized by regularly publishing detailed operational throughput data, allowing companies to actively track category-specific review speeds to optimize their precise filing window.

The short answer: pick the right regulatory pathway from day one and prepare a dossier that doesn’t trigger the clarification cycle. ANVISA’s legal review deadlines are 120 days for priority cases and 365 days for ordinary ones, set by Law 6360/1973. The five-year horizon companies complain about is almost never the rule itself, it is the result of filing under the wrong category, missing data that forces a fila de exigências (clarification cycle), or sitting in a pile of pending applications that, until recently, was growing faster than the agency could clear. That last piece is changing, and faster than most international applicants realize.

_{What is actually causing the five-year wait?}

In practice, three things stretch the clock. Companies file under the ordinary route when they could qualify for priority review and never apply for reclassification. They submit dossiers that mirror FDA or EMA submissions without adapting to ANVISA’s specific technical asks. That mismatch lands the file in successive clarification cycles, each one adding months. On top of that, they enter at the back of an already long line of pending review. By late 2025, several categories at ANVISA were running well past their legal targets, according to the agency’s own communications. That is what creates the headline figures, not the law itself.

_{Which fast-track pathways exist right now?}

Three pathways matter and choosing between them is most of the strategy.

Priority review under RDC 1.001/2025, published on December 11, 2025 and revoking the old RDC 204/2017, sets a 120-day target for medicines treating neglected, rare, emerging or re-emerging diseases; public health emergencies; serious debilitating conditions; and pediatric indications. The new rule also adds Phase I clinical trials run entirely in Brazil to the priority list, and lets ANVISA classify products as priority when there is a credible supply-shortage risk with public health impact, a meaningful expansion versus the previous regime.

Reliance is the second lever. Under RDC 741/2022 and its 2025 refinement (RDC 997/2025), ANVISA can lean on prior approvals from Equivalent Foreign Regulatory Authorities (AREEs), whose composition varies by product type. For medicine and biologic registration, the list now covers FDA, EMA, Health Canada, MHRA, Swissmedic, TGA, PMDA (for quality data only), and WHO Prequalification. For high-risk medical devices, it covers FDA, Health Canada, MHLW/PMDA, and TGA. For Good Manufacturing Practice (GMP) inspections, any PIC/S and ICH member authority qualifies, encompassing over 38 agencies globally. The same reliance logic extends across ANVISA's remit: food additive assessments (leaning on EFSA, FDA, Codex, and others under IN 344/2025), medical device GMP inspections (via MDSAP auditors and Mercosur authorities), and clinical trials, making it the broadest acceleration lever available across product categories. The agency has signaled it wants to widen and deepen this practice, and a dedicated reliance review track is now running through end-2026. For products already approved by a stringent authority, this is the single fastest legal route though ANVISA retains full decision-making sovereignty and accountability throughout, with reliance speeding the analysis, but not replacing it.

Third, RDC 205/2017 remains the dedicated rare-disease expedited pathway and has produced approvals in the 6-to-12-month range when the dossier is well-prepared.

_{Is the plan to clear pending applications actually moving the needle?}

Yes, more than skepticism would suggest. The agency’s Plano de Redução de Filas, launched in 2025, targeted halving the pending caseload within six months and normalizing flows within a year. The early results published by ANVISA show real progress: the medical-devices task force cut the post-registration pending applications by 40%, with January and February 2026 throughput hitting 1,111 petitions versus 509 in the same window of 2025, more than double. The radiopharmaceuticals pending review has been cleared to zero. For synthetic medicines, ANVISA projects 2025 will close as the highest-approval year since 2019. The plan also includes a R$25 million investment in AI tooling to support reviewers.

_{What separates a 12-month approval from a five-year one?}

Five concrete steps, drawn from Speyside’s LatAm regulatory work, separate the two timelines. First, file for priority designation explicitly, even where the product looks borderline, since RDC 1.001/2025 leaves room for case-by-case classification. Second, map the dossier to ANVISA’s structure before submission, not the FDA’s. Third, where a stringent-authority approval already exists, build the reliance request into the initial filing rather than holding it back as a fallback. Fourth, pre-empt the clarification cycle by addressing the technical points ANVISA flagged on comparable recent submissions in the same therapeutic class. Fifth, track the agency’s published throughput data, since ANVISA is increasingly transparent about which categories are moving and which still need attention, and that information should shape filing timing.

_{Where Speyside sees Brazil heading}

The direction of travel is clear. ANVISA is positioning itself closer to its reference peers in process design, while keeping its own bar on the local data that matters to it: pediatrics, Phase I and supply security. For companies that treat Brazil as a copy-paste of a US or European filing, timelines will continue to disappoint. For those who design the regulatory strategy around the pathway that actually fits the product’s access route in Brazil, 12 to 18 months is now a realistic target. Five years is increasingly a story about the old ANVISA, and, just as often, about filings that overlooked the local evidence and frameworks ANVISA weighs most heavily, not the one operating in 2026.

_{FAQ: Optimizing ANVISA Regulatory Pathways & Approval Speeds}

Q: What are the statutory legal review deadlines for product approval at ANVISA? A: Under Law 6360/1973, ANVISA operates under strict legal review mandates. The agency is legally required to complete reviews within 120 days for priority designation cases and 365 days for ordinary submissions.

Q: What is the primary cause of the multi-year delays that companies experience? A: Delays are almost exclusively driven by falling into successive technical clarification cycles (fila de exigências). This happens when international firms submit standard global dossiers (such as unmodified FDA or EMA templates) that do not account for ANVISA's specific technical guidelines or local data requirements.

Q: How does the "Optimized Pathway" or regulatory reliance mechanism function? A: This fast-track framework allows ANVISA to utilize the scientific evaluations already performed by trusted international reference authorities (such as the FDA, EMA, or PMDA). To utilize it, companies must formally embed a reliance request directly within their initial filing, rather than saving it as a late-stage fallback measure.

Q: Can any product qualify for the Priority Review Pathway? A: No. Priority status is governed by strict criteria under RDC 204/2017 and RDC 1.001/2025. However, because these regulations leave room for case-by-case evaluation on borderline products, companies should proactively build a comprehensive, evidence-based filing to explicitly request priority status from day one.

Q: How can Speyside help your company accelerate market entry through ANVISA? A: Speyside helps life sciences and healthcare companies bypass the clarification cycle by aligning global dossiers directly with ANVISA’s localized technical expectations before submission. We support clients by mapping agency throughput data, identifying strategic openings under RDC 1.001/2025, and managing regulatory affairs as an active corporate planning variable to transform market access from a bottleneck into a commercial differentiator.

‍